Drugs /
naxitamab
Overview
Clinical Trials
Naxitamab has been investigated in 8 clinical trials, of which 8 are open and 0 are closed. Of the trials investigating naxitamab, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open).
Ganglioside GD2 Positive and MYCN Amplification are the most frequent biomarker inclusion criteria for naxitamab clinical trials.
Neuroblastoma, osteosarcoma, and desmoplastic small round cell tumor are the most common diseases being investigated in naxitamab clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.